Immunologic control of HIV-1 through combination bNAbs and biologics.
通过 bNAb 和生物制剂的组合对 HIV-1 进行免疫控制。
基本信息
- 批准号:10544484
- 负责人:
- 金额:$ 159.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-05 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAdultAftercareAmino AcidsAnimal ModelAnimal TestingAnimalsAntibodiesAntibody-Dependent EnhancementAntigen PresentationAntigen-Antibody ComplexAntigensB-Cell LymphomasBLR1 geneBindingBinding SitesBiological AssayBiological ProductsCD8-Positive T-LymphocytesCardiovascular DiseasesCellsCellular ImmunityClinical ResearchDevelopmentDisease ProgressionDisease remissionDoseDrug KineticsFc domainFosteringFrequenciesGeneticGenetic TranscriptionHIVHIV Envelope Protein gp120HIV-1Half-LifeHealthHumoral ImmunitiesImmuneImmune responseImmune systemImmunityImmunologicsImmunotherapyImpaired cognitionIn VitroIndividualIndolentInfectionInfusion proceduresInnate Immune ResponseInterleukin-15InterruptionInterventionMacacaMeasuresMediatingModelingMonoclonal AntibodiesMusMutationNatural Killer CellsNon-Hodgkin&aposs LymphomaPatientsPersonsPhase I/II Clinical TrialPilot ProjectsPlasmaProliferatingPropertyProvirus IntegrationQualitative MethodsRefractoryRelapseSIVSafetyT cell responseTestingTimeV3 LoopVaccinesVariantViralViral PhysiologyViral reservoirViremiaVirusVirus DiseasesVirus Replicationadaptive immune responseanti-CD20antibody-dependent cell cytotoxicityantiretroviral therapybasecancer cellcomorbiditycytotoxichealthy volunteerimmunological statusimmunoregulationimprovedlymph nodesneutralizing antibodynonhuman primatenovelperipheral bloodpreventrecruitresponserituximabsimian human immunodeficiency virussuccesstrafficking
项目摘要
Project Summary
Despite the success of antiretroviral therapy (ART) in suppressing viral replication and preventing disease
progression, HIV-1 persists in a long-lived reservoir of latently infected cells that harbor integrated proviruses
which can be reactivated, resulting in the lifelong requirement of ART. Efforts to identify strategies to eradicate
or induce treatment-free long-term HIV-1 remission are critical. Broadly neutralizing antibodies (bNAbs) differ
from ART in that they can recruit immune effector functions through their Fc domains to accelerate clearance
of viruses and infected cells. In addition, immune complexes are potent immunogens that can foster
development of host immune responses. 3BNC117 and 10-1074 are bNAbs that bind to the CD4 binding site
(CD4bs) and to the base of the V3 loop in HIV-1 envelope gp-120. Both antibodies show exceptional breadth
and potency in vitro, and protect against or suppress infection in animal models. When administered during
early chimeric simian/human immunodeficiency virus (SHIV) infection, 3BNC117 and 10-1074 led to sustained
virologic control in about half of the tested animals. This effect was due to CD8+ T cell mediated control of
viremia, suggesting that the bNAbs exerted immune enhancing effects. In HIV-infected adults, three doses
3BNC117 and 10-1074 over 6 weeks maintained viral suppression for an average of 21 weeks in individuals
harboring antibody-sensitive viruses, including two individuals who continued to maintain viral suppression for
at least 11 months after ART discontinuation. The potential immune modulatory effects of bNAbs are
dependent of the availability of antigen. Fully suppressive ART reduces the frequency of infected cells
expressing envelope to levels that appear to be too low to induce immunity. In contrast, bNAb-mediated viral
suppression may allow sufficient antigen expression to trigger immunologic effects, and these effects are likely
to be enhanced when bNAbs are used in combination with molecules known to modulate immune responses
and induce viral transcription. We propose to test these concepts using N-803, an interleukin-15 superagonist,
which has immune modulatory properties, such as enhancement of antibody-dependent cell-mediated
cytotoxicity, and induces HIV-1 reactivation. This project aims to conduct two clinical studies to evaluate the
antiviral activity of the combination of the long-acting (“LS”) variants of 3BNC117 and 10-1074 in viremic HIV-
infected individuals, and to assess the ability of this long-acting dual-bNAb combination to produce sustained
viral remission when administered with the IL-15 superagonist, N-803, during ART interruption.
项目摘要
尽管抗逆转录病毒疗法(ART)在抑制病毒复制和预防疾病方面取得了成功,
随着疾病的进展,HIV-1在潜伏感染细胞的长期储存库中持续存在,这些细胞含有整合的前病毒
这些疾病是可以重新激活的,导致终生需要抗逆转录病毒治疗。
或诱导HIV-1长期免治疗缓解至关重要。广泛中和抗体(bNAb)
因为它们可以通过其Fc结构域募集免疫效应子功能以加速清除
病毒和受感染细胞的混合物。此外,免疫复合物是有效的免疫原,
宿主免疫反应的发展。3BNC117和10 - 1074是与CD4结合位点结合的bNAb
(CD4bs)和HIV-1包膜gp-120中V3环的碱基。两种抗体都显示出
并在动物模型中保护或抑制感染。给药时
早期嵌合猴/人免疫缺陷病毒(SHIV)感染,3BNC 117和10 - 1074导致持续的
在大约一半的测试动物中进行病毒学控制。这种效应是由于CD8 + T细胞介导的对
病毒血症,表明bNAb具有免疫增强作用。在感染艾滋病毒的成年人中,
3BNC 117和10 - 1074在6周内在个体中维持病毒抑制平均21周
携带抗体敏感病毒,包括两名继续维持病毒抑制的人,
ART停药后至少11个月。bNAb的潜在免疫调节作用是
这取决于抗原的可用性。完全抑制性ART降低了感染细胞的频率
表达包膜至似乎太低而不能诱导免疫的水平。相反,bNAb介导的病毒
抑制可能允许足够的抗原表达以触发免疫效应,并且这些效应可能是
当bNAb与已知调节免疫反应的分子联合使用时,
并诱导病毒转录。我们建议使用N-803来测试这些概念,N-803是一种白细胞介素-15超级激动剂,
其具有免疫调节特性,例如增强抗体依赖性细胞介导的
细胞毒性,并诱导HIV-1再活化。该项目旨在进行两项临床研究,以评估
3BNC 117和10 - 1074的长效("LS")变体的组合在病毒血症HIV-1中的抗病毒活性
感染的个体,并评估这种长效双bNAb组合产生持续的
在ART中断期间给予IL-15超激动剂N-803时的病毒缓解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marina Caskey其他文献
Marina Caskey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marina Caskey', 18)}}的其他基金
First-in-human study of a potent anti-HBsAg neutralizing antibody
强效抗 HBsAg 中和抗体的首次人体研究
- 批准号:
10550458 - 财政年份:2023
- 资助金额:
$ 159.68万 - 项目类别:
Defining the mechanisms of HIV resistance to bNAbs in humans
定义人类 HIV 对 bNAb 的耐药机制
- 批准号:
10659172 - 财政年份:2022
- 资助金额:
$ 159.68万 - 项目类别:
Defining the mechanisms of HIV resistance to bNAbs in humans
定义人类 HIV 对 bNAb 的耐药机制
- 批准号:
10446159 - 财政年份:2022
- 资助金额:
$ 159.68万 - 项目类别:
REACH: Research Enterprise to Advance a Cure for HIV
REACH:推进艾滋病毒治疗的研究企业
- 批准号:
10618402 - 财政年份:2021
- 资助金额:
$ 159.68万 - 项目类别:
REACH: Research Enterprise to Advance a Cure for HIV
REACH:推进艾滋病毒治疗的研究企业
- 批准号:
10469458 - 财政年份:2021
- 资助金额:
$ 159.68万 - 项目类别:
REACH: Research Enterprise to Advance a Cure for HIV
REACH:推进艾滋病毒治疗的研究企业
- 批准号:
10313563 - 财政年份:2021
- 资助金额:
$ 159.68万 - 项目类别:
Immunologic control of HIV-1 through combination bNAbs and biologics.
通过 bNAb 和生物制剂的组合对 HIV-1 进行免疫控制。
- 批准号:
9804264 - 财政年份:2019
- 资助金额:
$ 159.68万 - 项目类别:
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir
3BNC117 和 10-1074 抑制 HIV-1 复制并减少病毒库
- 批准号:
9897465 - 财政年份:2017
- 资助金额:
$ 159.68万 - 项目类别:
3BNC117 mAb in HIV-infected subjects on combination ART
3BNC117 mAb 用于接受联合 ART 治疗的 HIV 感染受试者
- 批准号:
9232973 - 财政年份:2015
- 资助金额:
$ 159.68万 - 项目类别:
3BNC117 mAb in HIV-infected subjects on combination ART
3BNC117 mAb 用于接受联合 ART 治疗的 HIV 感染受试者
- 批准号:
8926535 - 财政年份:2015
- 资助金额:
$ 159.68万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 159.68万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 159.68万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 159.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 159.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 159.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)